Ambrx, Inc. clinical trials
Acquired by Johnson & Johnson, Mar 7, 2024 · source ↗
The registry lists 4 studies whose lead sponsor is Ambrx, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 9, 2026.
Before and after it joined Johnson & Johnson
- First submitted before Ambrx, Inc. became part of Johnson & Johnson
- 4
- First submitted after Ambrx, Inc. became part of Johnson & Johnson
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Ambrx, Inc.4 studies
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Johnson & Johnson studies →
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Active, not recruitingNCT04829604Phase 2
Sponsor listed in the registry: Ambrx, Inc. · First submitted before Ambrx, Inc. became part of Johnson & Johnson
- A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)CompletedNCT03255070Phase 1
Sponsor listed in the registry: Ambrx, Inc. · First submitted before Ambrx, Inc. became part of Johnson & Johnson
- ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)WithdrawnNCT05041972Phase 2
Sponsor listed in the registry: Ambrx, Inc. · First submitted before Ambrx, Inc. became part of Johnson & Johnson
- Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).CompletedNCT00778518Phase 2
Sponsor listed in the registry: Ambrx, Inc. · First submitted before Ambrx, Inc. became part of Johnson & Johnson